AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
EU approves Nvidia’s $700M acquisition of Israeli startup Run:ai
2
Israeli tech’s top 10 funding rounds of 2024: Wiz sets another record
3
Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive
4
The Wiz of GenAI security? “Lasso has the potential to be a once-in-a-decade company in cyber”
5
Israel will "experience a 'baby boom' of innovation" in 2025, says RUNI Ventures
More news

Teva

20 stories about Teva
ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva’s 10-year turnaround takes shape with stunning trial results

18.12.24|Sophie Shulman
Duvakitug signals a brighter future for the Israeli pharma giant. 
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva shares jump as its most promising drug shows exceptional trial results

17.12.24|Sophie Shulman
Duvakitug, designed to treat colitis and Crohn’s disease, exceeded expectations and positions Teva to compete in the $28 billion global market for inflammatory bowel disease treatments.
בורסה תל אביב מסחר

How dual-listed companies boost profits without earning more

08.12.24|Uri Tal Tenne
The creative accounting tricks Israeli firms use to inflate earnings.
Noam Solomon Immunai

Immunai and Teva launch multi-tear AI collaboration for smarter drug development

14.11.24|CTech
The partnership will utilize Immunai’s cutting-edge immune system mapping tools to enhance precision in immunology and oncology trials.  
ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva soars with double-digit growth in Q3, raises annual forecast

06.11.24|Sophie Shulman
Strong sales of Austedo and Ajovy push Teva’s revenues above expectations, with the company forecasting up to $16.5 billion in 2024.
קופקסון זריקה תרופה טבע

Teva to pay $450 million over Copaxone price inflation

11.10.24|Sophie Shulman
Settlement with the Department of Justice addresses price hikes from $17,000 to $85,000 per year for the multiple sclerosis drug. 
לוגו חברת טבע ב מטה החברה ב תל אביב 20.2.24

Teva's vision 2025: Building on momentum for future market leadership

04.08.24|Sophie Shulman
Richard Francis’ strategic plan aims to transform Teva into a powerhouse of growth and innovation.
ריצ'רד פרנסיס נשיא ו מנכ"ל חברת טבע

Teva posts impressive Q2 results, ups 2024 revenue forecast

31.07.24|Sophie Shulman
Strong sales of Austedo and Ajovy lead to double-digit growth for the Israeli pharma company.
הנהלת מאנדיי קום MONDAY COM

How Monday overtook NICE and why Teva is on course to becoming Israel's highest-valued company

24.07.24|Sophie Shulman
While Wall Street transitions from growth stocks to value stocks, the balance of power among Israeli giants is also shifting. This reflects the speed at which the market punishes companies and rewards those leading growth processes, returning to profitability, or correctly identifying emerging fields.
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva settles $750 million tax dispute with Israeli authorities

25.06.24|Sophie Shulman
The deal with the Israel Tax Authority resolves all pending litigation related to taxes payable for the years from 2008 to 2020
ריצ'רד פרנסיס מנכ"ל טבע

Teva shares continue to surge, climb to highest mark in more than five years on Q1 results

08.05.24|Sophie Shulman
AUSTEDO continues to be Teva's main growth engine and its flagship drug, with annual growth of 67% in sales
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Why are Teva shares surging and how does it plan to keep it up

04.04.24|Uri Tel Tenne
Since the beginning of the year, Teva's shares have risen by about 36%, and are among the best performing stocks on the Tel Aviv Stock Exchange. Why is this happening and how is the company's CEO planning to build on the momentum?
מניית טבע בורסת ניו יורק מניה

Teva has sights on $12.2 billion Humira market after receiving FDA approval for arthritis injection

25.02.24|Meir Orbach
The Israeli pharma company and Iceland’s Alvotech announced that the SIMLANDI injection has been approved as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva CEO: "The company played not to lose, now we’ll play to win"

21.02.24|Sophie Shulman
Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory
ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Teva expects lower profits in 2024 despite a strong Q4 performance

31.01.24|Reuters
"We are gaining momentum, and now it's about executing as we did in 2023 in 2024," said CEO Richard Francis
ריצ'רד פרנסיס מנכ"ל טבע

Teva CEO: Israel’s production capacity has not been affected by the war

08.11.23|Sophie Shulman
The Israeli pharmaceutical company’s revenues grew by 7% in the last quarter to $3.9 billion, according to a report it recently published.
יונתן קולבר, מנהל שותף של ION מפעל טבע בכפר סבא

$300 million Teva bet: Will Norway's wealth fund and ION regret investing in the pharma giant?

11.09.23|Almog Azar
ION, which manages investments for the Norwegian wealth fund, began a buying spree of Teva shares at the beginning of the year
מפעל טבע בקנדה

Closure of another criminal case will help Teva's new CEO to focus on return to growth

22.08.23|Sophie Shulman
The pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations
ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Teva profit plummets, stock slides

10.05.23|Reuters
Teva plans to unveil a new strategy next week which CEO Francis said would "build on Teva's strong foundations, key strengths, and sets the stage for long-term growth"
ריצ'רד פרנסיס מנכ"ל טבע החדש על רקע אתר חברת טבע בכפר סבא

Schultz kept Teva away from the abyss, but couldn't find a runway to growth

22.11.22|Sophie Shulman
Kare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines
More Articles